SLS HealthcareBeta data

SELLAS Life Sciences Group, Inc.

$8.87+3.74%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 1.8B USD
Enterprise value: 1.7B USD
Full-time employees: 13

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 861% from December 2022 to August 2026.
SELLAS Life Sciences had 861% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.SELLAS Life Sciences had 861% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, SELLAS Life Sciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
SELLAS Life Sciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Little borrowing. Debt is 0.01× equity vs a peer median of 0.2×.Debt is 0.01× equity vs peers 0.2×.
SELLAS Life Sciences has among the least debt in its peer group relative to shareholders' equity.

StockQuotient Score

—Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Share count up 529.9% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-2.7%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-1.6%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield7.7%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.52

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio18.83×

Yahoo FinanceOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.01×

Yahoo FinanceReported value33% base weight · Z-score 1.06Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about SELLAS Life Sciences

Is SELLAS Life Sciences getting weaker?: Its latest SEC filing (Aug 11, 2026) got weaker in some ways: share count up 529.9%.
How is SELLAS Life Sciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -2.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -2.7% vs peers 1.5% (weaker than 100% of peers).
Is SELLAS Life Sciences growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is SELLAS Life Sciences?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is SELLAS Life Sciences?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 18.83× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 18.83× vs peers 2.59× (stronger than 95% of peers). Beta 2.52 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.52 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2023 · filed Aug 11, 2026 · compared with the quarter ended Sep 30, 2023

Got weaker

Share count up 529.9% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Revenue (12 months)	0 USD	0 USD	—
Net income (12 months)	−38.3M USD	−32.5M USD	−15.3%
Cash	4.0M USD	138.3M USD	+3385.6%
Shares outstanding	32.1M	201.9M	+529.9%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	97.4%	90.0%	—	—	—	—
Operating margin	-332.8%	-4195.0%	—	—	—	—
Net margin	-272.4%	-4130.1%	—	—	—	—
Return on assets (ROA)	-78.8%	-197.2%	-600.4%	-158.9%	-34.3%	▲ 125 pts
Return on equity (ROE)	-101.7%	-851.4%	—	-326.3%	-37.9%	▲ 288 pts
Current ratio	4.63×	1.14×	0.23×	1.72×	10.72×	▲ 524%

SLS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Shareholders being diluted. Shares outstanding up 861% from December 2022 to August 2026.

SELLAS Life Sciences had 861% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.SELLAS Life Sciences had 861% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, SELLAS Life Sciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

SELLAS Life Sciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Little borrowing. Debt is 0.01× equity vs a peer median of 0.2×.Debt is 0.01× equity vs peers 0.2×.

SELLAS Life Sciences has among the least debt in its peer group relative to shareholders' equity.

Questions investors ask about SELLAS Life Sciences

Is SELLAS Life Sciences getting weaker?

Its latest SEC filing (Aug 11, 2026) got weaker in some ways: share count up 529.9%.

How is SELLAS Life Sciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -2.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -2.7% vs peers 1.5% (weaker than 100% of peers).

Is SELLAS Life Sciences growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is SELLAS Life Sciences?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is SELLAS Life Sciences?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 18.83× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 18.83× vs peers 2.59× (stronger than 95% of peers). Beta 2.52 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.52 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

0 USD

0 USD

—

Net income (12 months)

−38.3M USD

−32.5M USD

−15.3%

Cash

4.0M USD

138.3M USD

+3385.6%

Shares outstanding

32.1M

201.9M

+529.9%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

97.4%

90.0%

—

Operating margin

-332.8%

-4195.0%

—

Net margin

-272.4%

-4130.1%

—

Return on assets (ROA)

-78.8%

-197.2%

-600.4%

-158.9%

-34.3%

▲ 125 pts

Return on equity (ROE)

-101.7%

-851.4%

—

-326.3%

-37.9%

▲ 288 pts

Current ratio

4.63×

1.14×

0.23×

1.72×

10.72×

▲ 524%